Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. (BOLT): 5 pipeline candidates · ~9 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.1 months
D/E 1.42 · 0% dilution
Lead: Phase 2
5 candidates
N/A
N/A
A transparent, data-derived signal for Bolt Biotherapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8.7M
Cash
$13.3M
Quarterly Burn
$8.0M
Runway
9.1 mo
Revenue
$26K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| bdc-3042 | Phase 1 |
| cemiplimab | Phase 1 |
| pegfilgrastim | Phase 2 |
| sbt777101 | Phase 1 |
| torl-1-23 | Phase 2 |
Frequently asked questions
How many drug candidates are in Bolt Biotherapeutics, Inc.'s pipeline?
Bolt Biotherapeutics, Inc. (BOLT) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Bolt Biotherapeutics, Inc.'s lead drug candidate?
Bolt Biotherapeutics, Inc.'s most advanced tracked candidate is bdc-3042 (Phase 1) for Triple Negative Breast Cancer.
What is Bolt Biotherapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Bolt Biotherapeutics, Inc. has approximately 9.1 months of cash runway.
What is Bolt Biotherapeutics, Inc.'s market capitalization?
Bolt Biotherapeutics, Inc.'s market capitalization is approximately $8.7M.
Who is the CEO of Bolt Biotherapeutics, Inc.?
Mr. William P. Quinn is the chief executive officer of Bolt Biotherapeutics, Inc. (BOLT).
Get the full picture on Bolt Biotherapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.